

Therapeutic Opportunities in Glycoscience





Institute of Biological Chemistry, Academia Sinica·中央研究院生物化學研究所 Institute of Biochemical Sciences, National Taiwan University·國立臺灣大學生化科學研究所

Contact: Nancy Liu (liukchun@gate.sinica.edu.tw / 02-2785-5696#2061)



Prof. Choh-Hao Li (1913-1987)



Dr. Choh-Hao Li graduated from the University of Nanking in 1933 and received his Ph.D. in Chemistry from the University of California, Berkeley in 1938. He joined the staff in Berkeley immediately thereafter and rose through the academic ranks to become Professor of Biochemistry in 1949. The world-famous Institute, Hormone Research Laboratory was organized at the Berkeley campus for him in 1950, and later on moved to UCSF in 1967. Dr. Li served as the Director of the Laboratory for thirty-three years until his retirement in 1983. However, he continued to conduct his research at his new Institute, Molecular Endocrinology Laboratory in UCSF until his death on November 28. 1987.

Dr. Li was among the first to isolate and identify eight of the nine hormones of the anterior pituitary. He isolated and synthesized the human pituitary growth hormone in 1971, the largest protein molecule synthesized at that time. The synthesis of the human growth hormone was hailed at the time as a scientific breakthrough, with tremendous possibilities in many areas of medical research. The pituitary gland, a small gland at the base of the brain, controls nearly every function in the body. The gland has been implicated in cancer, rheumatoid arthritis, allergies and metabolic diseases. In addition, Dr. Li and his associates did research on many other hormones used in disease treatment. In 1976, Dr. Li discovered β-endorphin, a substance produced in the brain that acts as a painkiller. He not only published over 1,000 scientific papers, but was also editor of many journals, and series of books.

In Taiwan, Dr. Li also made great contributions in initiating protein research in early 1958 and founding of biochemistry programs as he served on the Scientific Advisory Board of the Institute of Biological Chemistry, Academia Sinica, Taiwan, as well as the National Science Council of Taiwan. Dr. Li continued to give his endless efforts promoting the progress of protein research here in Taiwan until his death. This memorial lectureship is thus established as an annual event and leveraged to keep this unique strength.



李卓皓 博士 (1913-1987)

李卓皓院士紀念演講會是由中央研究院生物化學研究所、臺灣大學生化科學研究所,以及台灣生物化學及分子生物學學會共同創辦。此演講會目的為紀念李卓皓博士在生物化學研究的貢獻,並推動台灣在分子層次研究蛋白質的發展。一年一度的演講會邀訪對蛋白質研究有重大貢獻之世界知名學者來台演講。

李卓皓博士1933年畢業於南京大學,並於1938年獲頒美國加州大學柏克萊分校化學博士學位。他 随即加入該校開始其研究生涯,並於1949年升任生物化學教授。柏克萊分校於1950年為他成立了 世界知名的荷爾蒙研究實驗室,此實驗室後來在1967年遷移至加州大學舊金山分校。至1983年退 休為止,李博士領導該實驗室長達33年的時間。此後直到1987年11月28日逝世之前,他仍於舊 金山分校內所設分子內分泌學研究室繼續進行研究。

腦下垂體的九種荷爾蒙中,就有八種是由李博士首先發現並分離。他於1971年成功合成人體生長 荷爾蒙,為當時人工合成的最大蛋白質,並為醫藥科學研究帶來重大突破與貢獻。腦下垂體位於 人腦底部中央位置,此微小瞭體分泌的荷爾蒙能控制人體幾乎所有的功能,並與癌症、風溼性關 節炎、過敏及多種代謝疾病相關。李博士與許多專家合作,將荷爾蒙運用在多種疾病的治療。他 於1976年發現β-腦內啡,這是一種由大腦分泌具止痛功能的物質。李博士不但發表了1000多篇 研究論文,遺擔任許多科學期刊與書籍系別的編輯。

早在1958年李卓皓教授應胡適博士之邀回國以蛋白質化學與腦下腺荷爾蒙為題在臺大講學八週共 24次演講,介紹蛋白質研究為主的最新生物科學發展概況,帶給國內生物科學新方向之啟示。李 教授內相關單位議國內應加速發展生物化學研究及人才培育,這成為中研院生化所及臺大生化 科學所成立的最大動力。李教授擔任中研院生化所設所諮詢委員會主任委員,直接參與籌畫,正 式成所後擔任學術諮詢委員會召集人直到過世為止,晚年仍持續推動台灣蛋白質研究。為了保持 這頁重點研究,相關單位於是創辦李卓皓院士紀念演講,成為每年四月的活動。



Prof. Carolyn Bertozzi

Anne T. and Robert M. Bass Professor, Stanford University

2022 Nobel in Chemistry Laureate

Carolyn Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology (by courtesy) at Stanford University, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University coincident with the launch of Stanford's Sarafan ChEM-H Institute.

Prof. Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on developing new therapeutic modalities that target disease-related glycobiology. She founded the field of bioorthogonal chemistry, for which she shared the 2022 Nobel Prize in Chemistry. Her group has invented targeted enzyme therapeutics for immune oncology, Lysosome Targeting Chimeras (LYTACs) for extracellular targeted protein degradation, antibody-lectin chimeras (AbLecs) for therapeutic applications, and site-specific bioconjugation methods for synthesis of next-gen antibody-drug conjugates. Her lab has also developed glycoproteomics technologies for disease biomarker discovery, point-of-care diagnostics for tuberculosis, and ultrasensitive antibody detection methods that are being used to diagnose early onset diabetes and viral infections. Her academic work has launched 12 co-founded biotechnology companies.

Prof. Bertozzi has been recognized with many honors and awards. She is an elected member of the Institute of Medicine, National Academy of Sciences, National Academy of Inventors and American Academy of Arts and Sciences. In addition to the Nobel Prize, she received the Welch Award in Chemistry, Heineken Prize for Biochemistry and Biophysics, Lemelson-MIT Prize, and a MacArthur Foundation Fellowship. She received the 2024 Priestley Medal from the American Chemical Society.

Therapeutic Opportunities in Glycoscience

Cell surface glycans constitute a rich biomolecular dataset that drives both normal and pathological processes. Their "readers" are glycan-binding receptors that can engage in cell-cell interactions and cell signaling. Our research focuses on mechanistic studies of glycan/receptor biology and applications of this knowledge to new therapeutic strategies. Our recent efforts center on pathogenic glycans in the tumor microenvironment and new therapeutic modalities based on the concept of targeted degradation.